Selected 3A4 Inhibitors/Cisapride
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process cisapride properly.
What might happen:
Your blood levels of cisapride may increase and cause life-threatening effects to your heart.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. They may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Agenerase (amprenavir) Capsules US prescribing information. GlaxoSmithKline May, 2005.
2.Reyataz (atazanavir sulfate) US prescribing information. Bristol-Myers Squibb Company August, 2013.
3.Reyataz (atazanavir sulfate) Australian product information. Bristol-Myers Squibb Pharmaceuticals January 8, 2004.
4.Prezista (darunavir) US prescribing information. Tibotec Inc. November, 2013.
5.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline February, 2013.
6.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. February, 2011.
7.Norvir (ritonavir) US prescribing information. Abbott Laboratories November, 2012.
8.Prepulsid (cisapride) US prescribing information. Janssen Pharmaceutica Products, L.P. January, 2000.
9.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories January, 2013.
10.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.
11.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. February, 2012.
12.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. May, 2013.
13.Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) prescribing information. Gilead Sciences, Inc. October, 2013.
14.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.